​

1. Brock BA, Mir H, Flenaugh EL, Oprea-Ilies G, Singh R, Singh S. Social and Biological Determinants in Lung Cancer Disparity. Cancers (Basel). 2024 Jan 31;16(3):612. doi: 10.3390/cancers16030612.

2. Haynes T, Oprea-Ilies G, Manne U, Singh R, Singh S, Mir H. The interplay of pineal hormones and socioeconomic status leading to colorectal cancer disparity. Transl Oncol. 2022 Feb;16:101330. doi: 10.1016/j.tranon.2021.101330. Epub 2022 Jan 3.

3. Mir H, Singh S. Neutrophils: a roadblock for immunotherapy. Nat Rev Cancer. 2022 Jul;22(7):378-379. doi: 10.1038/s41568-022-00464-3.

4. Singh SP, Ali NB, Lundberg L. Smart and Adaptive Architecture for a Dedicated Internet of Things Network Comprised of Diverse Entities: A Proposal and Evaluation. Sensors (Basel). 2022 Apr 14;22(8):3017. doi: 10.3390/s22083017.

5. Singh S, Singh K. Atherosclerosis, Ischemia, and Anticancer Drugs. Heart Views. 2021 Apr-Jun;22(2):127-133. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_45_20. Epub 2021 Aug 19.

6. Mir H, Kapur N, Gales DN, Sharma PK, Oprea-Ilies G, Johnson AT, Singh R, Singh S. CXCR6-CXCL16 Axis Promotes Breast Cancer by Inducing Oncogenic Signaling. Cancers (Basel). 2021 Jul 16;13(14):3568. doi: 10.3390/cancers13143568.

7. Bari S, Chineke I, Darwin A, Umar A, Jim H, Muzaffar J, Singh S, Kucuk O. Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211051622. doi: 10.1177/15347354211051622.

8. Mir H, Singh S. CCL25 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2021;1302:99-111. doi: 10.1007/978-3-030-62658-7_8.

9. Singh S, Tiwari J, Jaiswal D, Sharma AK, Singh J, Singh V, Singh J. Nucleophilic Acylation with Aromatic Aldehydes to 2 Bromoacetonitrile: An Umpolung Strategy for the Synthesis of Active Methylene Compounds. Curr Org Synth. 2020;17(7):518-524. doi: 10.2174/1570179417666200615153536.

10. Thomas JK, Mir H, Kapur N, Bae S, Singh S. CC chemokines are differentially expressed in Breast Cancer and are associated with disparity in overall survival. Sci Rep. 2019 Mar 8;9(1):4014. doi: 10.1038/s41598-019-40514-9.

11. Saunders IT, Mir H, Kapur N, Singh S. Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways. Cancer Cell Int. 2019 Apr 15;19:98. doi: 10.1186/s12935-019-0820-3. eCollection 2019.

12. Mir H, Kaur G, Kapur N, Bae S, Lillard JW Jr, Singh S. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Sci Rep. 2019 Feb 21;9(1):2527. doi: 10.1038/s41598-019-38766-6.

13. Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW Jr, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Lett. 2019 Jul 10;454:1-13. doi: 10.1016/j.canlet.2019.04.001. Epub 2019 Apr 8.

14. King Thomas J, Mir H, Kapur N, Singh S. Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer. Cancers (Basel). 2019 Nov 25;11(12):1857. doi: 10.3390/cancers11121857.

15. Singh S, Vatsa D, Tomar S, Aneja GK, S Arya TV. Cardiac complications in people living with human immunodeficiency virus/acquired immunodeficiency syndrome and their association with CD4+ T-cell count - A cross-sectional study. Indian J Sex Transm Dis AIDS. 2018 Jan-Jun;39(1):23-27. doi: 10.4103/ijstd.IJSTD_18_16.

16. Carriere PP, Kapur N, Mir H, Ward AB, Singh S. Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer. Int J Oncol. 2018 Oct;53(4):1442-1454. doi: 10.3892/ijo.2018.4489. Epub 2018 Jul 19.

17. Ward AB, Mir H, Kapur N, Gales DN, Carriere PP, Singh S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol. 2018 Jun 14;16(1):108. doi: 10.1186/s12957-018-1400-z.

18. King J, Mir H, Singh S. Association of Cytokines and Chemokines in Pathogenesis of Breast Cancer. Prog Mol Biol Transl Sci. 2017;151:113-136. doi: 10.1016/bs.pmbts.2017.07.003. Epub 2017 Sep 28.

19. Kapur N, Mir H, Clark Iii CE, Krishnamurti U, Beech DJ, Lillard JW, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016 Jun 14;114(12):1343-51. doi: 10.1038/bjc.2016.113. Epub 2016 May 5.

20. Dickinson-Copeland CM, Wilson NO, Liu M, Driss A, Salifu H, Adjei AA, Wilson M, Gyan B, Oduro D, Badu K, Botchway F, Anderson W, Bond V, Bacanamwo M, Singh S, Stiles JK. Correction: Heme-Mediated Induction of CXCL10 and Depletion of CD34+ Progenitor Cells Is Toll-Like Receptor 4 Dependent. PLoS One. 2016 Jan 14;11(1) doi: 10.1371/journal.pone.0147460. eCollection 2016.

21. Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW Jr, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016;15(6):819-26. doi: 10.1080/15384101.2016.1148836.

22. Singh R, Kapur N, Mir H, Singh N, Lillard JW Jr, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering. Oncotarget. 2016 Feb 9;7(6):7343-53. doi: 10.18632/oncotarget.6944.

23. Mir H, Singh R, Kloecker GH, Lillard JW Jr, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015 Apr 30;6(12):9985-98. doi: 10.18632/oncotarget.3194.

24. Dickinson-Copeland CM, Wilson NO, Liu M, Driss A, Salifu H, Adjei AA, Wilson M, Gyan B, Oduro D, Badu K, Botchway F, Anderson W, Bond V, Bacanamwo M, Singh S, Stiles JK. Heme-Mediated Induction of CXCL10 and Depletion of CD34+ Progenitor Cells Is Toll-Like Receptor 4 Dependent. PLoS One. 2015 Nov 10;10(11)

    . doi: 10.1371/journal.pone.0142328. eCollection 2015.

25. Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW Jr, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014 Oct 30;5(20):10170-9. doi: 10.18632/oncotarget.2526.

26. Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW Jr. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Int J Oncol. 2014 Dec;45(6):2232-40. doi: 10.3892/ijo.2014.2688. Epub 2014 Sep 30.

27. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014 Apr;141(4):514-30. doi: 10.1111/imm.12194.

28. Kumar Goyal N, Goel A, Sankhwar SN, Mandal S, Singhai A, Singh S. Cheek metastasis from a bladder tumor: unusual presentation of an aggressive disease. Urologia. 2013 Sep-Dec;80(4):317-21. doi: 10.5301/urologia.5000022. Epub 2013 Jun 24.

29. Verma S, Saraf S, Himanshu D, Singh S. Takayasu's arteritis presenting as digital gangrene of right hand. BMJ Case Rep. 2013 Jan 10;2013

    . doi: 10.1136/bcr-2012-007854.

30. El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW Jr. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Mol Cancer. 2013 Jun 18;12:64. doi: 10.1186/1476-4598-12-64.

31. Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW Jr. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine. 2012 Feb 1;30(6):1181-90. doi: 10.1016/j.vaccine.2011.12.020. Epub 2011 Dec 14.

32. El-Haibi CP, Singh R, Gupta P, Sharma PK, Greenleaf KN, Singh S, Lillard JW Jr. Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. J Proteomics Bioinform. 2012;5(8):177-184. doi: 10.4172/jpb.1000232.

33. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW Jr. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011 May;38(5):1279-85. doi: 10.3892/ijo.2011.953. Epub 2011 Feb 23.

34. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW Jr, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 3;9:46. doi: 10.1186/1477-7819-9-46.

35. Singh R, Lillard JW Jr, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 2011 Jun 1;3(4):1569-82. doi: 10.2741/246.

36. Singh R, Stockard CR, Grizzle WE, Lillard JW Jr, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.

37. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW Jr. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22;8:62. doi: 10.1186/1477-7819-8-62.

38. Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW Jr, Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res. 2010 Jun 17;3:15. doi: 10.1186/1757-2215-3-15.

39. Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW Jr. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One. 2010 Feb 25;5(2). doi: 10.1371/journal.pone.0009432.

40. Sharma PK, Singh R, Novakovic KR, Eaton JW, Grizzle WE, Singh S. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer. 2010 Nov 1;127(9):2020-30. doi: 10.1002/ijc.25219.

41. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW Jr. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010 Apr 22;9:85. doi: 10.1186/1476-4598-9-85.

42. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW Jr. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009 Nov 15;125(10):2288-95. doi: 10.1002/ijc.24574.

43. Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW Jr. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. Mol Cancer Ther. 2009 Jan;8(1):178-84. doi: 10.1158/1535-7163.MCT-08-0643.

44. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW Jr. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009 Sep 28;283(1):29-35. doi: 10.1016/j.canlet.2009.03.022. Epub 2009 Apr 17.

45. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW Jr. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008 Jan;28(1):31-43. doi: 10.1089/jir.2007.0059.

46. Singh R, Singh S, Lillard JW Jr. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci. 2008 Jul;97(7):2497-523. doi: 10.1002/jps.21183.

47. Sakthivel SK, Singh UP, Singh S, Taub DD, Igietseme JU, Lillard JW Jr. CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 2008 Aug 13;8:136. doi: 10.1186/1471-2180-8-136.

48. Sakthivel SK, Singh UP, Singh S, Taub DD, Novakovic KR, Lillard JW Jr. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines. 2008 Oct 28;6:6. doi: 10.1186/1476-8518-6-6.

49. Singh UP, Singh R, Singh S, Karls RK, Quinn FD, Taub DD, Lillard JW Jr. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 2008 Jun 4;9:25. doi: 10.1186/1471-2172-9-25.

50. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW Jr. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007 Aug;75(8):3722-8. doi: 10.1128/IAI.01770-06. Epub 2007 May 14.

51. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006 Jul 10;6:181. doi: 10.1186/1471-2407-6-181.

52. Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W 3rd, Sampson JS, Stiles JK, Taub DD, Lillard JW Jr. CCL5 modulates pneumococcal immunity and carriage. J Immunol. 2006 Feb 15;176(4):2346-56. doi: 10.4049/jimmunol.176.4.2346.

53. Sarfo BY, Armah HB, Irune I, Adjei AA, Olver CS, Singh S, Lillard JW Jr, Stiles JK. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malar J. 2005 Dec 16;4:63. doi: 10.1186/1475-2875-4-63.

54. He Q, Moore TT, Eko FO, Lyn D, Ananaba GA, Martin A, Singh S, James L, Stiles J, Black CM, Igietseme JU. Molecular basis for the potency of IL-10-deficient dendritic cells as a highly efficient APC system for activating Th1 response. J Immunol. 2005 Apr 15;174(8):4860-9. doi: 10.4049/jimmunol.174.8.4860.

55. Palaniappan R, Singh S, Singh UP, Sakthivel SK, Ades EW, Briles DE, Hollingshead SK, Paton JC, Sampson JS, Lillard JW Jr. Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun. 2005 Feb;73(2):1006-13. doi: 10.1128/IAI.73.2.1006-1013.2005.

56. Singh UP, Singh S, Boyaka PN, McGhee JR, Lillard JW Jr. Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rbeta interactions. J Leukoc Biol. 2004 Dec;76(6):1240-7. doi: 10.1189/jlb.0903444. Epub 2004 Sep 8.

57. Singh UP, Singh S, Ravichandran P, Taub DD, Lillard JW Jr. Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts. J Immunol. 2004 Nov 1;173(9):5509-16. doi: 10.4049/jimmunol.173.9.5509.

58. Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004 Dec;84(12):1666-76. doi: 10.1038/labinvest.3700181.

59. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW Jr. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004 Dec 15;10(24):8743-50. doi: 10.1158/1078-0432.CCR-04-0266.

60. Singh UP, Singh S, Iqbal N, Weaver CT, McGhee JR, Lillard JW Jr. IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res. 2003 Oct;23(10):591-600. doi: 10.1089/107999003322485099.

61. Singh UP, Singh S, Taub DD, Lillard JW Jr. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol. 2003 Aug 1;171(3):1401-6. doi: 10.4049/jimmunol.171.3.1401.

62. Lillard JW Jr, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood. 2003 Feb 1;101(3):807-14. doi: 10.1182/blood-2002-07-2305. Epub 2002 Sep 12.

63. Pandey M, Sharma LB, Singh S, Shukla VK. Erythrocyte membrane fatty acid profile and saturation index in gallbladder carcinogenesis: a case-control study. World J Surg Oncol. 2003 May 7;1(1):5. doi: 10.1186/1477-7819-1-5.